A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients With HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat With Regorafenib
Latest Information Update: 03 Jan 2022
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Acronyms ReDos HCC
- 10 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 08 Oct 2021 Planned End Date changed from 1 Jul 2023 to 28 Feb 2022.
- 08 Oct 2021 Planned primary completion date changed from 1 Dec 2022 to 31 Jan 2022.